sector medic suppli devic
weak clinic updat lay foundat
messag alreadi pre-announce sale focu
call busi trend januari outlook
former answer great procedur flat yoy meanwhil
manag will comment guid bottom end
new rang provid three week ago mark time last
month lower sale outlook suggest us compani
still earli process address issu encourag new
clinical/pipelin updat call believ step eventu drive
earli color suggest littl improv impella volum
previous disclos third quarter tale two halv solid growth
octob patient growth follow sharp declin util wake
two neg data present aha novemb net result crosscurr
 impella revenu growth quarter increas patient
treat januari much better volum vs decemb flat yoy
basi given slow start quarter manag expect sale come
low end alreadi reduc rang provid three week ago impli
ww revenu growth flat modestli perform domest
suggest still much work restor momentum
busi encourag step compani take
call manag announc two new random control trial high-risk pci
protect iv ami shock recov iv address gap clinic evid
support level guidelin recommend impella use p-iv random high-risk
pci patient schedul undergo plan complet revascular either impella-
support pci pci without hemodynam support meanwhil r-iv random post-
ami cardiogen shock patient either impella-support pci treatment protocol
inotrop ecmo etc compani expect enrol p-iv begin next
month start r-iv may delay site run
already-underway stemi dtu trial enrol patient date success
believ three studi could firmli establish impella standard care
larg market opportun data readout far away help
current controversi weigh busi applaud manag will
answer critic ambiti clinic program
meantim ramp physician outreach educ effort
combat neg percept creat aha present sens
biggest impact data confus refer physician lead
fewer patient sent evalu protect pci mean
tougher task ahead embark multi-c roadshow tout clinic evid
support impella use problem lay interventionalist ultim
believ compani good stori tell limit aha
studi wealth real-world evid impella outcom technolog
enhanc also help manag plan roll smartassist
anoth custom expand avail new impella pump
compani also target fda approv new expand sheath late
long-await ecp pump slate begin first-in-man implant april year
howev encourag take step necessari turn
busi around predict speed compani success
assuag physician concern futur slope impella adopt dust
settl difficult stage
page analyst certif import disclosur
given uncertainti lower estim model call
adjust ep yoy total revenu cc compar
prior forecast ep sale longer term project
revenu growth rebound gain forecast
assum impact new clinic trial detail potenti
stemi indic expans timelin three studi remain unclear
point also far cri growth trajectori prior past year
compani grow sale compound-annual-growth-rate howev think
disrupt busi past quarter come transient factor
continu believ headwind also coincid impella transit
differ phase adopt curv one challeng climb
earli adopt phase may ultim requir high-level clinic evid
compani set collect result comfort assum
robust re-acceler point
stay sidelin stock share current trade revis
ntm revenu estim level commensur top-lin trajectori vs
low-teen growth rate forecast result see risk/reward
particularli attract despit stock under-perform past year vs
 maintain neutral rate
page analyst certif import disclosur
leader mechan circulatori support dedic enabl safer
treatment high-risk patient cardiovascular diseas recov injur heart
muscl estim patient receiv one compani famili impella
heart pump last year yet believ scratch surfac impella
long-term potenti estim market opportun includ
impella smallest heart pump world design provid temporari
hemodynam support patient undergo high-risk procedur whose cardiac
function compromis sinc impella first receiv approv
impella famili pump use support ten thousand peopl
abiom revenu grow compound-annual-growth-rate period howev think fourth
straight quarter disappoint us impella growth make increasingli like
busi transit earli adopt phase flatter part penetr
curv believ manag take right step drive deeper penetr
chang like take time effect
share trade ntm revenu estim high end
multipl rang peer smid-cap med-tech group view multipl
commensur top line growth trajectori manag
guid result expect stock difficult time sustain
posit momentum visibl improv signific near-term catalyst
outsid quarterli earn report horizon see better opportun elsewher
maintain neutral rate
upsid risk rate includ potenti impella adopt exceed street
expect pipelin advanc improv long-term outlook failur
competit materi potenti larg player bring abiom
downsid risk rate includ potenti impella adopt fall short
street forecast pipelin setback clinic failur weaken abiom long-term
outlook faster-than-expect progress potenti impella competitor
premium valuat leav littl margin error view
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
servic
revenu geographi
 unit
 unit indic
compani report guggenheim secur llc estim
page analyst certif import disclosur
